Dopamine depleters in the treatment of hyperkinetic movement disorders

References

• Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol. 2009;8:844–856.
   PubMed Web of Science ®Google Scholar
• Peña MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 2011;26:147–152.
   PubMed Web of Science ®Google Scholar
• Vijayakumar D, Jankovic J. Drug-induced dyskinesia, Part 2: treatment of tardive dyskinesia. Drugs. 2016 May;76(7):779–787.
   PubMed Web of Science ®Google Scholar
• Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology totreatment. Tremor Other Hyperkinet Mov (N Y). 2013 Jul 12;3. pii: tre-03-161-4138-1. doi:10.7916/D88P5Z71.
   Google Scholar
• Garay RP, Citrome L, Samalin L, et al. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opin Pharmacother. 2016;17(7):921–936.
   PubMed Web of Science ®Google Scholar
• Ankenman R, Salvatore MF. Low dose alpha-methyl-para-tyrosine (AMPT) in the treatment of dystonia and dyskinesia. J Neuropsychiatry Clin Neurosci. Winter 2007;19(1):65–69.
   PubMed Web of Science ®Google Scholar
• Lawal HO, Krantz DE. SLC18: vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2–3):360–372.
   PubMed Web of Science ®Google Scholar
• Benarroch EE. Monoamine transporters: structure, regulation, and clinical implications. Neurology. 2013 Aug 20;81(8):761–768.
   PubMed Web of Science ®Google Scholar
• Vaht M, Kiive E, Veidebaum T, et al. A functional vesicular monoamine transporter 1 (VMAT1) gene variant is associated with affect and the prevalence of anxiety, affective, and alcohol use disorders in a longitudinal population-representative Birth Cohort Study. Int J Neuropsychopharmacol. 2016 Jul 5;19(7). pii: pyw013. doi:10.1093/ijnp/pyw013.
   PubMed Web of Science ®Google Scholar
• Markos SM, Failla MD, Ritter AC, et al. Genetic variation in the vesicular monoamine transporter: preliminary associations with cognitive outcomes after severe traumatic brain injury. J Head Trauma Rehabil. 2016. [Epub ahead of print].
   PubMedGoogle Scholar
• Yang X, Xu P, Zhao Q, et al. Polymorphism in the vesicular monoamine transporter 2 gene decreases the risk of Parkinson’s disease in Han Chinese men. Parkinsons Dis. 2015;2015:903164.
   PubMedGoogle Scholar
• Lizarraga LE, Cholanians AB, Phan AV, et al. Vesicular monoamine transporter 2 and the acute and long-term response to 3,4-(±)-methylenedioxymethamphetamine. Toxicol Sci. 2015 Jan;143(1):209–219.
   PubMed Web of Science ®Google Scholar
• Rilstone JJ, Alkhater RE, Minassian BA. Brain dopamine-serotonin vesicular transport disease and its treatment. N Engl J Med. 2013;368:543–550.
   PubMed Web of Science ®Google Scholar
• Wijemanne S, Jankovic J. Dopa-responsive dystonia–clinical and genetic heterogeneity. Nat Rev Neurol. 2015 Jul;11(7):414–424.
   PubMed Web of Science ®Google Scholar
• German CL, Baladi MG, McFadden LM, et al. Regulation of the dopamine and vesicular monoamine transporters: pharmacological targets and implications for disease. Pharmacol Rev. 2015 Oct;67(4):1005–1024.
   PubMed Web of Science ®Google Scholar
• Marecos C, Ng J, Kurian MA. What is new for monoamine neurotransmitter disorders? J Inherit Metab Dis. 2014 Jul;37(4):619–626.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Sherer T. The future of research in Parkinson disease. JAMA Neurol. 2014 Nov;71(11):1351–1352.
   PubMed Web of Science ®Google Scholar
• Hsiao IT, Weng YH, Hsieh CJ, et al. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography. JAMA Neurol. 2014 Jun;71(6):758–766.
   PubMed Web of Science ®Google Scholar
• Arena JE, Stoessl AJ. Optimizing diagnosis in Parkinson’s disease: radionuclide imaging. Parkinsonism Relat Disord. 2016 Jan;22(Suppl 1):S47–S51.
   Google Scholar
• Jimenez-Shahed J, Jankovic J. Tetrabenazine for treatment of chorea associated with Huntington’s disease. Expert Opin Orphan Drugs. 2013;1:423–436.
   Web of Science ®Google Scholar
• Belleau B, Burba J, Pindell M, et al. Effect of deuterium substitution in sympathomimetic amines on adrenergic responses. Science. 1961 Jan 13;133(3446):102–104.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011;11:1509–1523.
   PubMed Web of Science ®Google Scholar
• Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007 Jan 15;22(2):193–197.
   PubMed Web of Science ®Google Scholar
• Shen V, Clarence-Smith K, Hunter C, et al. Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with Huntington’s and other diseases. Tremor Other Hyperkinet Mov (N Y). 2013 Oct;22:3.
   Google Scholar
• Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66:366–372.
   PubMed Web of Science ®Google Scholar
• Xenazineusa.com/HCP/MOA.
   Google Scholar
• Kenney C, Hunter C, Davidson A, et al. Short-term effects of tetrabenazine on chorea associated with Huntington’s disease. Mov Disord. 2007 Jan;22(1):10–13.
   PubMed Web of Science ®Google Scholar
• Schwartz DE, Bruderer H, Rieder J, et al. Metabolic studies of tetrabenazine, a psychotropic drug in animals and man. Biochem Pharmacol. 1966;15:645–655.
   PubMed Web of Science ®Google Scholar
• Mehanna R, Hunter C, Davidson A, et al. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013;28:210–215.
   PubMed Web of Science ®Google Scholar
• Fasano A, Bentivoglio AR. Tetrabenazine. Expert Opin Pharmacother. 2009;10:2883–2896.
   PubMed Web of Science ®Google Scholar
• Frank S. Treatment of Huntington’s disease. Neurotherapeutics. 2014 Jan;11(1):153–160.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Roos RA. Chorea associated with Huntington’s disease: to treat or not to treat? Mov Disord. 2014 Sep 15;29(11):1414–1418.
   PubMed Web of Science ®Google Scholar
• Baizabal-Carvallo JF, Stocco A, Muscal E, et al. The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord. 2013 Apr;28(4):543–547.
   PubMed Web of Science ®Google Scholar
• Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurology. 2009;9:62.
   PubMed Web of Science ®Google Scholar
• Ferrara JM, Mostile G, Hunter C, et al. Effect of tetrabenazine on motor function in patients with Huntington disease. Neurol Ther. 2012;1:5.
   PubMedGoogle Scholar
• Fekete R, Davidson A, Jankovic J. Clinical assessment of the effect of tetrabenazine on functional scales in huntington disease: a pilot open label study. Tremor Other Hyperkinet Mov (N Y). 2012;2. pii: tre-02-86-476-4. doi:10.7916/D8DN43SC.
   Google Scholar
• Fekete R, Davidson A, Ondo WG, et al. Effect of tetrabenazine on computerized dynamic posturography in Huntington disease patients. Parkinsonism Relat Disord. 2012;18:896–898.
   PubMed Web of Science ®Google Scholar
• Reilmann R, Rumpf S, Beckmann H, et al. Huntington’s disease: objective assessment of posture–a link between motor and functional deficits. Mov Disord. 2012;27:555–559.
   PubMed Web of Science ®Google Scholar
• Dorsey R, Biglan K, Eberly S, et al. Use of tetrabenazine in Huntington disease patients on antidepressants or with advanced disease: results from the TETRA-HD study. PLoS Curr. 2011 Nov 13;3:RRN1283.
   PubMedGoogle Scholar
• Dorsey ER, Brocht AF, Nichols PE, et al. Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study. J Huntingtons Dis. 2013;2(4):509–515.
   PubMedGoogle Scholar
• Kenney C, Hunter C, Mejia N, et al. Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol. 2006;29:259–264.
   PubMed Web of Science ®Google Scholar
• Albin RL, Koeppe RA, Wernette K, et al. Striatal [11C]dihydrotetrabenazine and [11C]methylphenidate binding in Tourette syndrome. Neurology. 2009;72:1390–1396.
   PubMed Web of Science ®Google Scholar
• Wijemanne S, Wu LJ, Jankovic J. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord. 2014 Jan;29(1):126–130.
   PubMed Web of Science ®Google Scholar
• Yoo HK, Joung YS, Lee JS, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette’s disorder. J Clin Psychiatry. 2013 Aug;74(8):e772–e780.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Therapeutic developments for tics and myoclonus. Mov Disord. 2015 Sep 15;30(11):1566–1573.
   PubMed Web of Science ®Google Scholar
• Thenganatt MA, Jankovic J. Recent advances in understanding and managing Tourette syndrome. F1000Res. 2016 Feb 9;5. pii: F1000 Faculty Rev-152. doi:10.12688/f1000research.7424.1.
   PubMedGoogle Scholar
• Kenney C, Hunter C, Mejia N, et al. Tetrabenazine in the treatment of Tourette syndrome. J Ped Neurol. 2007;5:9–13.
   Google Scholar
• Benchoua A, Trioulier Y, Diguet E, et al. Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II. Hum Mol Genet. 2008;17:1446–1456.
   PubMed Web of Science ®Google Scholar
• Wang H, Chen X, Li Y, et al. Tetrabenazine is neuroprotective in Huntington’s disease mice. Mol Neurodegener. 2010 Apr;26(5):18.
   Web of Science ®Google Scholar
• Lohr KM, Bernstein AI, Stout KA, et al. Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9977–9982.
   PubMed Web of Science ®Google Scholar
• Howland RH. Deuterated drugs. J Psychosoc Nurs Ment Health Serv. 2015 Sep;53(9):13–16.
   Web of Science ®Google Scholar
• Mullard A. Deuterated drugs draw heavier backing. Nat Rev Drug Discov. 2016 Apr;15(4):219–221.
   PubMed Web of Science ®Google Scholar
• Stamler D, Bradbury M, Brown F. The pharmacokinetics and safety of deuterated-tetrabenazine. Neurology. 2013;80:P07.210.
   Web of Science ®Google Scholar
• Huntington Study Group. Frank S, Testa Cm Stamler E, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016 Jul 5; 316(1): 40–50.
   PubMed Web of Science ®Google Scholar
• Claassen DO, Stamler D, Sung V. Alternatives for reducing chorea in Huntington disease, a long-term trial (ARC-HD): updated Week 8 results for the switch cohort. Presented at the 20th International Congress of Parkinson’s Disease and Movement Disorders; 2016 Jun 21; Berlin, Germany.
   Google Scholar
• Jankovic J, Jimenez-Shahed J, Budman C, et al. Deutetrabenazine in tics associated with Tourette syndrome. Tremor Other Hyperkinet Mov (N Y). 2016;6. doi:10.7916/D8M32W3H.
   Google Scholar
• Jeon S, Walkup JT, Woods DW, et al. Detecting a clinically meaningful change in tic severity in Tourette syndrome: a comparison of three methods. Contemp Clin Trials. 2013 Nov;36(2):414–420.
   PubMed Web of Science ®Google Scholar
• Anderson KE, Factor SA, Jimenez-Shahed J, et al. Addressing involuntary movements in tardive dyskinesia (AIM-TD): A randomized, double-blind, placebo-controlled, fixed-dose study of deutetrabenazine for the treatment of moderate to severe tardive dyskinesia (TD). Poster presented at the 29th US Psychiatric and Mental Health Congress; October 21–24, 2016; San Antonio, Texas. Poster 206.
   Google Scholar
• Müller T. Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert Opin Investig Drugs. 2015 Jun;24(6):737–742.
   PubMed Web of Science ®Google Scholar
• O’Brien CF, Jimenez R, Hauser RA, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord. 2015 Oct;30(12):1681–1687.
   PubMed Web of Science ®Google Scholar
• Factor SA, Hauser RA, Siegert S, et al. KINECT 3: A randomized, double-blind, placebo-controlled phase 3 trial of valbenazine (NBI-98854) for tardive dyskinesia. Presented at the 20th International Congress of Parkinson’s Disease and Movement Disorders; 2016 Jun 21; Berlin, Germany.
   Google Scholar
• http://www.prnewswire.com/news-releases/neurocrine-announces-successful-completion-of-phase-ib-t-force-study-of-vmat2-inhibitor-nbi-98854-in-adolescents-and-children-with-tourette-syndrome-300194060.html.
   Google Scholar
• Chen S, Zhang XJ, Xie WJ, et al. A New VMAT-2 inhibitor NBI-641449 in the treatment of Huntington disease. CNS Neurosci Ther. 2015 Aug;21(8):662–671.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Medical treatment of dystonia. Mov Disord. 2013 Jun 15;28(7):1001–1012.
   PubMed Web of Science ®Google Scholar
• Luciano AY, Jinnah HA, Pfeiffer RF, et al. Treatment of myoclonus-dystonia syndrome with tetrabenazine. Parkinsonism Relat Disord. 2014 Dec;20(12):1423–1426.
   PubMed Web of Science ®Google Scholar
• Fasano A, Bove F, Lang AE. The treatment of dystonic tremor: a systematic review. J Neurol Neurosurg Psychiatry. 2014 Jul;85(7):759–769.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Jong D, Davis A. Comparison of weight gain in treatments for Tourette syndrome: tetrabenazine versus neuroleptic drugs. J Child Neurol. 2008 Apr;23(4):435–437.
   PubMed Web of Science ®Google Scholar
• Burke RE, Reches A, Traub MM, et al. Tetrabenazine induces acute dystonic reactions. Ann Neurol. 1985;17:200Y202.
   Google Scholar
• LeWitt PA. Tardive dyskinesia caused by tetrabenazine. Clin Neuropharmacol. 2013 May-Jun;36(3):92–93.
   PubMed Web of Science ®Google Scholar
• Citrome L. Breakthrough drugs for the interface between psychiatry and neurology. Int J Clin Pract. 2016;70(4):298–299.
   PubMed Web of Science ®Google Scholar
• Spitz MC, Jankovic J, Killian JM. Familial tic disorder, parkinsonism, motor neuron disease, and acanthocytosis: a new syndrome. Neurology. 1985 Mar;35(3):366–370.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Caskey TC, Stout JT, et al. Lesch-Nyhan syndrome: a study of motor behavior and cerebrospinal fluid neurotransmitters. Ann Neurol. 1988 May;23(5):466–469.
   PubMed Web of Science ®Google Scholar
• Remington G, Kapur S, Foussias G, et al. Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2012;32:95–99.
   PubMed Web of Science ®Google Scholar
• Howell LL, Negus SS. Monoamine transporter inhibitors and substrates as treatments for stimulant abuse. Adv Pharmacol. 2014;69:129–176.
   PubMedGoogle Scholar
• Nickell JR, Siripurapu KB, Vartak A, et al. The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse. Adv Pharmacol. 2014;69:71–106.
   PubMedGoogle Scholar
• Kaur N, Kumar P, Jamwal S, et al. Tetrabenazine: spotlight on drug review. Ann Neurosci. 2016 Sep;23(3):176–185.
   PubMed Web of Science ®Google Scholar